CRP levels are strong, independent predictors of cardiovascular risk and can enhance risk stratification. Jupiter enrolled 17 802 apparently healthy middle-aged men and women with CRP levels over 2.0 mg/l, and LDL less than 130 mg/dl. They were randomized to receive rosuvastatin 20 mg daily or placebo, and followed for a primary endpoint of nonfatal myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death for 1.9 years. Rosuvastatin lowered CRP (37%), LDL (50%), nonfatal myocardial infarction (55%), nonfatal stroke (48%), hospitalization and revascularization (47%), all-cause mortality (20%), and benefited women and minority subgroups. Rosuvastatin was tolerated relatively well, with a small rise in physician-reported diabetes. Jupiter data suggest that patients with high levels of CRP should receive statins. Approximately 4.3% of the population satisfies Jupiter inclusion criteria. A review of the assessment of cardiovascular risk is under way at the National Institutes of Health to guide practitioners.
The plenary session of the American Heart Association Annual Scientific Session last year began with a landmark report, The JUPITER Trial-Rosuvastatin in the Prevention of Cardiovascular Events Among 17 802 Men and Women with Elevated Levels of C-Reactive Protein, showing a surprisingly high reduction in cardiovascular events among healthy individuals with elevated C-reactive protein (CRP) as a result of rosuvastatin therapy. The study, simultaneously published online in the New England Journal of Medicine [Ridker et al. 2008a] , generated data which were remarkable in several ways, and will surely impact both the thinking and practice of primary prevention. The characteristics of the Jupiter study, an acronym for Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin, have been previously described [Ridker et al. 2007a; Ridker, 2003 ]. Debate about Jupiter and its implications has continued unabated through 2009 as well, which only attests to its potential significance.
Jupiter enrolled 17 802 apparently healthy middle-aged men (50 years) and women (60 years) from 1315 sites in 26 countries. Patients were free of diabetes and heart disease, with normal low-density lipoprotein levels (LDL < 130 mg/dl), but high hs-C reactive protein (CRP) levels (2.0 mg/l, median, 4.2 mg/l).
Participants were randomly assigned into two groups: either treated with rosuvastatin, 20 mg daily, or placebo. Salient baseline patient data are summarized in Table 1 . Enrollees were followed for a primary composite end point of myocardial infarction, hospitalization for unstable angina, heart-related death, arterial revascularization or stroke. Although planned as a 4-year study, the trial was stopped after a median follow-up time of 1.9 years based upon advice from an independent monitoring board and study steering committee.
Rosuvastatin lowered CRP levels by 37% (down to a 12-month mean, in the treated group, of 2.2; lowered LDL by 50% (down to a 12-month mean, in the treated group, of 55) and sharply decreased the number of cardiovascular events and all-cause mortality. At the end of 1.9 years, rosuvastatin therapy significantly lowered the primary composite end point by 44% compared with placebo. In particular, there was a 55% lowering of nonfatal MI, 48% fall in the risk of nonfatal stroke, and a 47% fall in the risk of serious cardiac events (Table 2 ). The reduction in vascular risk was greater in Jupiter than in previous statin trials.
The number of physician-reported new cases of diabetes was 270 in the rosuvastatin group and 216 in the untreated group, with a small rise in median glycosylated hemoglobin (A1c), previously noted in statin studies. Ten instances of myopathy, and one case of rhabdomyolysis were reported in the treatment group, with nine and none, respectively, in the untreated group. At the end of the trial, 75% of participants were taking rosuvastatin. The number needed to treat for 2 years to prevent one primary event was 95; treatment for 4 years lowered it to 31, and for 5 years, the number to treat fell to 25.
Groundbreaking features of the Jupiter study Unique aspects are:
. Jupiter was the first prospective, doubleblind, placebo-controlled randomized clinical trial of its size sufficiently powered for conclusions about use of rosuvastatin in healthy subjects (absence of criteria for major risk factors, according to evidence-based guidelines) for primary prevention. . The metabolic substrate of enrollees was fairly representative of current 'healthy' Americans, somewhat overweight, tending to the metabolic syndrome with subclinical risk factors. . Reductions in cardiovascular events were observed in both African-and Hispanic-American participants. . Women enjoyed all benefits of therapy. There has been considerable debate recently about the relative efficacy of statin drugs among women, and some have questioned the wisdom of using this class of agents at all for women with established LDL elevations, citing a poor reward/risk ratio. In particular, in women without heart disease, thus far there has been little evidence statins improve outcomes. . Remarkable effectiveness in reduction of both LDL and CRP correlated with nearly double the improvement in events than predicted from prior statin trials.
Changes in thinking about inflammation and atherosclerosis
During the past two decades, atherosclerosis has been increasingly regarded as an inflammatory process in which LDL is involved, rather than an obligatory consequence of LDL elevation alone. There is no doubt that LDL is a major risk factor for disease, and that aggressive lowering of LDL reduces cardiovascular risk and optimizes clinical outcomes. Evidence does not establish unequivocally whether lowering LDL is inherently anti-inflammatory or not, but definitely leans toward the former. Practitioners who believe that inflammatory indices need not be taken into account clinically focus only on LDL lowering in their patients. However, a tsunami of accumulating basic science and clinical data indicates otherwise; there is a rich literature demonstrating that lowering levels of inflammatory markers, including some cytokines, are associated with beneficial outcomes [Packard and Libby, 2008] . The many anti-inflammatory, pleiotropic properties of statins, independent of their lipid-lowering effect, substantially contribute to their diverse actions [Pierre-Paul and Gahtan, 2003; Ulrich and Liao, 2003; Liao, 2002] .
The Jupiter study, taken together with other evidence, strongly suggests that the biologically 'ideal' (or goal, according to current data) LDL level may be 70, perhaps even closer to 50, and the 'ideal' CRP may be <2.0 for cardiovascular prevention. Curiously, these probably correspond to typical values in our forebears during the Mesolithic-Pleistocene, or hunter-gather, period, when lifestyle (diet, activity, stress, etc.) more closely matched metabolic constraints of human genetic instructions, which invites the question, is the difference fully offset by 20 mg of rosuvastatin?
The challenge that lies ahead is assimilation and proper placement of the Jupiter data within the framework of current treatment protocols and guidelines. Who should receive CRP testing and when, and in what new situations should statins be employed? Which statins will be able to achieve these results, and in what doses? Can we simply say, all patients with elevated CRP levels should be receiving potent statins? Should we also monitor CRP levels along with lipids on a continuing basis?
Place of CRP measurement in clinical practice
Evidence-based research has earned CRP a high standing among 'newer' markers of cardiovascular risk, because it reflects the intensity of the inflammatory process and has the ability to predict future cardiovascular events, adding to the prognostic information beyond traditional risk factors at each level of LDL and Framingham risk score [Mora and Ridker, 2006; Yeh and Palusinski, 2003; Bhatt, 2008] . CRP levels are strong, independent predictors of cardiovascular events: lower CRP levels are associated with fewer such events, independent of LDL levels, and withdrawal of statin therapy results in both higher CRP levels and elevated risk [van der Harst et al. 2007] . CRP is superior to other markers, such as soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6), apolipoprotein B, and the total cholesterol/HDL ratio. For these reasons, inclusion of CRP values in the Reynolds Risk Score for women, validated using the Women's Health Study database, offers improved accuracy for global cardiovascular risk prediction in about 30% of women, compared to the traditional 10-year Framingham-based/2001 NCEP ATP-III risk score [Blumenthal et al. 2007; Ridker et al. 2007b] . A corresponding risk score for men, incorporating both CRP value and parental history, similarly improves accuracy of risk assessment [Ridker et al. 2008b] .
Currently, in patients with low cardiovascular risk (<10% risk of a hard cardiac event within 10 years), lifestyle measures for primary prevention are usually recommended, and outcomes may not be rigorously followed. In high-risk patients (>20% risk of hard events, myocardial infarction, or coronary artery disease death within 10 years) aggressive treatment to lower risk should begin immediately. Until now, current recommendations have discouraged requesting CRP levels to guide therapy, unless patient risk fell in an intermediate range, in which case further risk stratification is suggested. CRP is but one of several available tests that may refine therapeutic choices, which include lipoproteinassociated phospholipase A 2 level measurement [Anderson, 2008; Corson et al. 2008; Davidson et al. 2008] , coronary artery calcium scoring [Hecht, 2008; Greenland et al. 2007; Lakoski et al. 2007; Budoff et al. 2006 ], and other atherosclerosis imaging techniques. CRP is a common, inexpensive test with no associated radiation exposure, easily followed over time.
The data from the Jupiter study clearly elevate the matter of inflammation and markers from nonclinical journal reports, placing it squarely into the arena of direct patient care, imploring the practicing physician to reclassify inflammatory biomarkers, such as CRP, as important clinical tools rather than experimental ones.
Reassessing LDL as a risk biomarker of choice
The limitations of LDL calculation as part of a conventional lipoprotein profile in assessing the presence of heart disease and predicting risk of future cardiac events are well known. The LDL level reported is estimated using the Friedewald formula, which is expressed in weight of LDL per deciliters of blood. Atherogenicity correlates more closely with the number of LDL particles rather than their weight. In addition, LDL is not the only atherogenic particle, so measurement of apolipoprotein B has been recommended. Further, additional risk is conferred by particles other than LDL not usually measured, such as lipoprotein 'little a' (Lp[a] ), and these are not influenced by statin therapy. More importantly, none of these measurements fully capture risk associated with inflammation, not reflected by either atherogenic particle number or weight.
When thinking about cardiovascular risk, there are total risk, separate risks (reflected differently by the variable we measure, whether it be LDL, apolipoprotein B, LDL particle number, etc.), reduced risk (also different for each therapeutic intervention used), and residual risk (which we cannot eliminate with current therapies). Improved methods assessing total risk, maximizing risk reduction, leaving minimal residual risk possible, is our real goal. Perhaps greater use of advanced lipid testing could raise the amount of total risk measured, but may still fall short of the goal needed for acceptable prevention. For instance, based upon the recent report of the international Residual Risk Reduction Initiative [Fruchart et al. 2008] , unless LDL levels alone drive treatment to the intensity called for in the Jupiter trial, substantial residual risk would remain unaddressed.
The Jupiter report not only underscores our failure to fully assess cardiovascular risk using estimated LDL values alone, but also our current failure to treat effectively, since a significant number of patients who presently fall in the 'low risk' category obviously go on to succumb to major cardiovascular events. The lay press repeatedly emphasizes the frequency of myocardial infarctions and sudden cardiac death in patients who have no elevations in LDL levels, to which there has been no easy answer thus far.
In patients with the metabolic syndrome now estimated at 32% of Americans and constituting 41% of the patients enrolled in Jupiter, who may not qualify for statin treatment under current guidelines, raised cardiovascular risk is undeniable, yet remains unaddressed. The cluster of risk factors known as the metabolic syndrome, represents the perfect storm of lifeshortening inflammatory and metabolic interplay [Gustafson et al. 2007] , and is driven by both obesity and under-diagnosed, undertreated components. The current approach to cardiometabolic risk reduction in patients with metabolic syndrome is to treat each component-visceral obesity, hypertension, dyslipidemia, insulin resistance or overt hyperglycemia. Jupiter now adds inflammation to the list of treatable components.
Critical questions remaining
Some reservations about the clinical applicability and usefulness of the Jupiter results are listed in Box 1, with commentary. Ongoing investigations will no doubt clarify many of these issues. The safety of a marked reduction in LDL levels in the treatment group, compared to prior use in secondary prevention over a prolonged period of time, is unknown. Some disappointment was expressed with early termination of the trial, which somewhat favored the positive results, and continuation would have produced some pertinent safety data. Since the number of patients treated presently with statins is unfortunately only a fraction of those qualifying for statin therapy under current guidelines, expansion of current indications would widen this gap, now due to 'clinical inertia'.
An editorial accompanying the original Jupiter report [Hlatky, 2008] emphasized that, when considering statin treatment, the absolute risk reductions are more important than relative risk reductions, and 120 patients required 1.9 years of treatment in the Jupiter study to prevent one cardiovascular event.
Finally, the 20% improvement in all cause mortality among the treated group in Jupiter is noteworthy. Although not fully appreciated, the prognosis of patients with 'minor' CRP elevations is not good, spanning a wide variety of conditions, not only cardiometabolic risk [Kushner et al. 2006 ]. In general, the discovery of a high CRP level should raise clinical diagnostic and/or therapeutic intensity, simultaneously seeking an explanation and a solution.
In a most poignant, confirmatory postscript to the Jupiter trial, released online after Jupiter results became available, Wilson and coworkers, using data from the 3006 patients in the Framingham Heart Offspring Study , investigated the potential benefit from adding CRP levels to prediction equations investigating vascular risk. They found that new hard coronary heart disease events and total events were significantly associated with higher CRP levels. In their review, reclassification of risk, incorporating CRP levels, enabled improvements in risk prediction/event discrimination over traditional values.
Box 1. Some potential reservations about applicability of results, with commentary.
. Results apply only to men >50 years and women >60 years old. However, since this is the first prospective study of its kind, applicability to other populations may simply await additional data collection from ongoing trials. . Prior screening of patients eliminated about 80% of the people considered for the study, although such control was also simultaneously one of its strengths. . Many clinicians feel that relatively few patients seen in typical practices have isolated elevations in CRP usually those with such elevations have abnormalities in traditional risk factors. Yet, a review of the U.S. National Health and Nutrition Examination Survey (NHANES) and other available data indicate that CRP elevations are highly prevalent. Significant numbers of such patients with unaddressed risk will undoubtedly rise with greater CRP use, especially in view of the relationship between adiposity and CRP levels. Overweight and obese children and adolescents constitute a sizeable and vulnerable subpopulation, which has reached critical public health thresholds. . Incidence of myopathy and rhabdomyolysis was unusually low compared with other studies and 'in the trenches' medical school-affiliated-lipid-clinic experience. The general impression among many clinicians is that these complications may be underreported. In this and other published studies, rosuvastatin, 20 mg, appeared to be tolerated as well as other, less potent, statins [Shepherd et al. 2007 ]. The discordance between clinical observations and published data is frequently cited as a major barrier to reaching lipid goals. . The higher reported incidence of diabetes in the rosuvastatin group is of unknown significance, but certainly of concern when evaluating long-term safety. , 2009] . In view of the widespread use of rosuvastatin in patients with diabetes, this issue requires resolution. . In view of the much lower absolute risk reduction, as compared with the published relative risk reduction, the potential cost of widespread CRP testing and statin treatment is high. Further economic analysis, with a number to treat of 25, must be compared to the costs of other testing and costly consequences of serious cardiovascular events in the composite end point. About 260 000 myocardial infarctions, strokes, revascularization procedures, and/or cardiac deaths might be avoided using the Jupiter protocol in the United States over a 5-year period. An additional 811 million persons in the United States would become eligible for statin treatment under Jupiter criteria. Analyses of 'returns' will understandably influence how these data impact future guidelines and utilization.
Conclusion
The current schematic for risk stratification needs some revision. Jupiter is a most significant, unprecedented study which provides unique and fresh information about successfully preventing the most important disease threatening citizens today. The data will likely result in a reassessment of current guidelines, and bring about a fundamental change in the approach to primary prevention. The Jupiter study, together with other available data, certainly indicates that CRP belongs much closer to the top of the physician's toolkit when performing a comprehensive risk assessment. CRP is not a perfect biomarker, but it is an extremely good one, capable of refining predictability and outcomes. Jupiter certainly validates the goal of 'dual targeting' to lower both LDL and CRP. In the broader view, Jupiter also cements the current concept that, in clinical heart disease, inflammation matters.
Recommendations of an expert panel assembled by the NHLBI to formally review cardiovascular risk factors, put forth in guidelines, will help practitioners reprioritize the laboratory and clinical procedures they request in caring for patients, and improve future practice patterns in this rapidly evolving field.
